Antonis was recently nominated for the Science Council’s 2025 CSci Award, a testament to the value the professional community places on integrity and cross-sector reflection.

🔗 Read the full story here: buff.ly/Aue7DNp

#CharteredWeek #CSci #FoodSafety #RiskAssessment #ScientificIntegrity

As we celebrate #CharteredWeek, Lauren’s experience shows that whether you are in a large firm or working independently, CSci is the gold standard for your professional reputation.

🔗 Discover how CSci can support your journey: buff.ly/DygMwM0

#CharteredWeek #CSci #SensoryScience #FoodScience

CSci also gave her the confidence to move between retail and manufacturing.
As we mark #CharteredWeek, her message is simple: invest in your skills and back your ambitions.

Ready to take the next step?

🔗 Start your application here: buff.ly/DygMwM0

#CharteredWeek #CSci #FoodScience

Read the full open letter here: bit.ly/40cMxtc

#CharteredWeek #ProfessionalStandards #CSci #FoodScience #PublicTrust #IFST

If you have been considering CSci, this is a good time to take a closer look.

Find out how CSci can support your career and your contribution to the food system here: buff.ly/qxI43sW

#CharteredWeek #CSci #FoodScience #FoodTechnology #ProfessionalDevelopment #IFST

During Chartered Week, we’ll share more member stories, career insights, and practical guidance on how to achieve CSci.

Take the next step in your professional journey and see how CSci can make a difference for you, your career, and the food system.

🔗 Learn more: buff.ly/Ur2RW6r

#CSci

COSCIENS Biopharma Inc. Reports Third Quarter 2025 Financial Results and Provides Strategic Initiatives Update COSCIENS Biopharma (TSX: CSCI, FINRA: CSCIF) reported Q3 2025 results and a strategic reset on Nov 11, 2025. The company had $8.5 million cash on Sept 30, 2025 and reported a consolidated net loss of $1.8 million for Q3 (vs. $5.8M in Q3 2024). Management implemented zero‑based budgeting and restructuring that reduced operating expenses by 59% year‑over‑year and improved gross margins by 700 basis points sequentially.COSCIENS voluntarily delisted from Nasdaq effective Sept 5, 2025, retains its TSX listing, applied to OTCQB for U.S. quotation, and intends to seek deregistration under Form 15‑F when eligible. The company is reassessing its portfolio, suspending the Juvente cosmeceuticals line, evaluating Macrilen pediatric options after FDA feedback, and completing Phase 2a for AvenActive with full results pending.

#CSCI COSCIENS Biopharma Inc. Reports Third Quarter 2025 Financial Results and Provides Strategic Initiatives Update

www.stocktitan.net/news/CSCI/cosciens-bioph...

COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update COSCIENS Biopharma (NASDAQ/TSX: CSCI) announced Q2 2025 financial results and strategic initiatives, including plans to voluntarily delist from Nasdaq while maintaining TSX listing. The company reported Q2 revenue of $2.7M, up 17% year-over-year, with a net loss of $2.4M.Key developments include a 27% workforce reduction, appointment of a new CEO and reconstituted Board of Directors, and implementation of zero-based budgeting. The company ended Q2 with $9.3M in cash. Their pharmaceutical pipeline includes Macrilen, which missed primary endpoints in Phase 3 DETECT trial, and AvenActive, currently in Phase 2a testing.The Nasdaq delisting, expected around September 4, 2025, aims to reduce costs and streamline operations, with plans to transition to OTC trading in the US while maintaining TSX listing.

#CSCI COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update

www.stocktitan.net/news/CSCI/cosciens-bioph...

CoreWeave’s Core Scientific acquisition sparks analyst doubts as stock dips CoreWeave’s $9 billion all-stock deal to acquire Core Scientific sent shares lower as analysts raised concerns over profitability and lingering crypto market volatility.

CoreWeave’s Core Scientific acquisition sparks analyst doubts as stock dips CoreWeave agreed to purchase Core Scientific in an all-stock deal valued at $9 billion.. @cosmicmeta.io #CSCI

https://u2m.io/bvdCMS2S

COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders COSCIENS Biopharma (NASDAQ: CSCI; TSX: CSCI), a life sciences company focused on cosmeceutical, nutraceutical and pharmaceutical products, has announced the results of its virtual annual general and special meeting of shareholders (AGSM).All six directors were successfully elected to the board, with most nominees receiving over 88% approval, except for Ronald W. Miller who received 68.75% of votes in favor. The shareholders also approved the appointment of Deloitte LLP as the company's auditor and passed a resolution approving the Amended and Restated Shareholder Rights Plan.As an Eligible Interlisted Issuer on the TSX, COSCIENS obtained an exemption from certain Canadian requirements regarding its long-term incentive plan, eliminating the need for shareholder approval of unallocated entitlements at the AGSM.

#CSCI COSCIENS Biopharma Announces Results of Virtual 2025 Meeting of Shareholders

www.stocktitan.net/news/CSCI/cosciens-bioph...

COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders COSCIENS Biopharma (NASDAQ/TSX: CSCI) has announced a significant board restructuring through a Resolution Agreement with Goodwood Inc., Goodwood Fund, and Puccetti Funds Management. The newly reconstituted board consists of six directors, with Peter H. Puccetti appointed as Chair. The agreement includes Goodwood's commitment to vote its 8.2% ownership (257,257 shares) in favor of the new board at the rescheduled 2025 Annual Meeting on June 30, 2025. The new board members bring extensive experience in pharmaceuticals, healthcare, and corporate governance, including Anthony Giovinazzo (former Cynapsus Therapeutics CEO), Ulrich Kosciessa (Photonamic CEO), Ronald W. Miller (former Roche Canada CEO), Peter Puccetti (Goodwood founder), Robert Seager (special situations advisor), and David Spear (Advancing Eyecare President). The Reconstituted Board aims to strengthen corporate governance and create shareholder value through active review of company prospects and opportunities.

#CSCI COSCIENS Biopharma Inc. Reconstitutes Board for Benefit of Shareholders

www.stocktitan.net/news/CSCI/cosciens-bioph...

Major Shake-Up Looms: Activist Fund Goodwood Launches Board Challenge at COSCIENS with 6 Director Nominations Activist investor Goodwood seeks to nominate 6 directors to COSCIENS board, signaling potential control battle. Board reviewing nominations. See latest developments.

#CSCI COSCIENS Biopharma Inc. Acknowledges Receipt of Intended Director Nominations from Goodwood for the Upcoming Annual and Special Meeting of Shareholders

www.stocktitan.net/news/CSCI/cosciens-bioph...

12/12 Special thanks to the patient donors and samples from VIVO Biobank and of course Brian Huntly & group 🤗 #CSCI @crukcamcentre.bsky.social | Work in my group is largely funded by Cancer Research UK #CRUK, Leukaemia UK
@leukaemiauk.bsky.social‬ and the European Hematology Association. 🙏🏻

COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update COSCIENS Biopharma (NASDAQ: CSCI) reported Q1 2025 financial results, showing a net loss of $3.7 million ($1.16 per share) compared to $1.4 million loss in Q1 2024. Revenue decreased to $1.5 million from $2.1 million year-over-year. The company ended Q1 with $13.8 million in cash. Key developments include successful Phase 1 results for Avenanthramides tablets and the launch of a Phase 2a clinical study. The company is advancing its nutraceutical portfolio with Oat Beta Glucan Chewable Bar and Yeast Beta Glucan Powder products. Operating expenses increased to $4.0 million from $2.7 million YoY, though quarter-over-quarter cash spend decreased from $3.6M to $2.6M following post-merger synergies. The company appointed Anna Biehn as CEO and has repositioned as a pure-play natural-based product company.

#CSCI COSCIENS Biopharma Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/CSCI/cosciens-bioph...

COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update COSCIENS Biopharma (NASDAQ: CSCI) has reported its Q4 and full-year 2024 financial results, marking a transformative year with a strategic repositioning as a pure-play natural-based product company. The company achieved revenues of $9.6M in 2024, up 35.2% from $7.1M in 2023.Key financial highlights include a cash position of $16.4M as of December 31, 2024, and a full-year net loss of $15.3M ($5.93 per share) compared to $3.5M loss in 2023. Operating expenses increased to $23.0M from $7.5M in 2023.Development updates include successful Phase 1 results for Avenanthramides Tablets, launch of Phase 2a clinical study, and progress in cosmeceuticals and nutraceuticals. The company has halted investment in pre-clinical programs and macimorelin development following negative Phase 3 DETECT-Trial results. New product launches planned include OBG chewable bars and YBG immune booster products in H2 2025.

#CSCI COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/CSCI/cosciens-bioph...

Regulatory Alert: COSCIENS Faces Management Trading Ban Over Missing Financial Reports COSCIENS receives MCTO amid delayed annual filings. Regular trading continues while management faces restrictions. Company targets April 7 completion. See impact analysis.

#CSCI COSCIENS Biopharma Inc. Announces Receipt of Management Cease Trade Order

www.stocktitan.net/news/CSCI/cosciens-bioph...

COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents COSCIENS Biopharma (NASDAQ/TSX: CSCI) announced potential delays in filing its annual financial statements, CEO/CFO certificates, and annual information form (Form 20-F) beyond the March 31, 2025 deadline. The delay stems from complications following the 2024 all-stock merger with Ceapro, requiring additional time for accounting procedure conversion and internal control review.The company identified material weaknesses in financial controls as of December 31, 2024, with deficiencies in the COSO framework principles. Additional review is also needed regarding the impact of prospective U.S. tariffs.As a precautionary measure, COSCIENS has applied for a management cease trade order (MCTO) with the Ontario Securities Commission. The company confirms this potential delay does not immediately affect its Nasdaq Capital Market listing and will issue bi-weekly status updates if an MCTO is granted.

#CSCI COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents

www.stocktitan.net/news/CSCI/cosciens-bioph...

COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents COSCIENS Biopharma (NASDAQ/TSX: CSCI) announced potential delays in filing its annual financial statements, CEO/CFO certificates, and annual information form (Form 20-F) beyond the March 31, 2025 deadline. The delay stems from complications related to their 2024 all-stock merger with Ceapro, requiring accounting procedure conversions to meet SEC reporting obligations.The company identified material weaknesses in financial controls as of December 31, 2024, with deficiencies in the COSO framework principles. Additional review is also needed regarding the impact of prospective U.S. tariffs. As a precautionary measure, COSCIENS has applied for a management cease trade order (MCTO) with the Ontario Securities Commission, though this won't affect non-management trading.While the delay doesn't immediately impact CSCI's Nasdaq Capital Market listing, the company commits to issuing bi-weekly status updates and completing the required filings as soon as possible.

#CSCI COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents

www.stocktitan.net/news/CSCI/cosciens-bioph...

Dr Helen Pain MBE CChem CSci FRSC

Dr Helen Pain #MBE #CChem #CSci #FRSC, Chief Executive of @rsc.org, welcomed everyone to #London 🇬🇧 and to Burlington House. She introduced the Royal Society of Chemistry and how #RSC supported #IUPAC activities and @iupac.org Divisions and Committees. Thank you Helen 👏

🌐 www.rsc.org/events/detai...

Bimanual upper limb task practice and Transcutaneous electrical stimulation enhance spinal plasticity and hand function after chronic cervical spinal cord injury Injuries to the spinal cord at the cervical level can lead to loss of upper limb function. Recent work suggests that combining functional task practice with Transcutaneous electrical stimulation of th...

Our preprint of a cross over trial combining #tscs and traditional physiotherapy in #cSCI. Here we use functional and neurophysiological measures #TMS to understand recovery of function #neurorehabilitation #neuromodulation #spinalcordinjury

www.medrxiv.org/content/10.1...

COSCIENS Biopharma Discontinues Key Drug Trial, Pivots to Natural Products Pipeline COSCIENS faces setback in macimorelin DETECT-trial, shifts focus to natural-based portfolio with multiple product launches planned. Management restructuring announced.

#CSCI COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization

www.stocktitan.net/news/CSCI/cosciens-bioph...

I recall when I still in bachelor course, I asked my professor about my major to take. My choice was Finace or Marketing because I was Business Administration student. However, my professor storongly recommended to change Faculty to Computer science. I went Finance. He was right.
#CTO #CFO #CS #CSCI

Cypher System Creature Index - Monte Cook Games Cypher System Creature Index Looking for just the right creature for your next encounter? There are so many choices—especially since […]

www.montecookgames.c...
#cyphersystem #csci #cyphersystemcreatureindex